Commercial preparations and handling of botulinum toxin type A and type B.
The recognition of botulinum toxin as a therapeutic tool has revolutionized the approach to facial esthetics. In the 1970s, Dr. Alan B. Scott pioneered the use of botulinum toxin type A (BTX-A) for strabismus. This discovery led to further studies examining other clinical applications of BTX-A and, more recently, botulinum toxin type B (BTX-B). Despite its widespread use and the more than two decades of experience with BTX-A, controversy remains over the preparation and handling of the toxin.